Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
Active, not recruiting · NCT04120766 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging | Cognition Disorders, Cognitive Dysfunction, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hippocampal Sclerosis, Malformations of Cortical Development, Group I, Mild Cognitive Impairment, brain disorder, central nervous system disorder, central nervous system malformation, cerebral cortical dysplasia, cognitive disorder, dementia, nervous system disorder, psychiatric disorder | Active, not recruiting | Phase 2 | 2025-12-15 | NCT04120766 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Gregory Jicha, MD, PhD | 1 |
| National Institute on Aging (NIA) | 571 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Kentucky | Lexington | United States | 10 |